This clinical trial is focused on studying a skin condition called hidradenitis suppurativa, which is a chronic inflammatory disease that causes painful lumps under the skin, often in areas like the armpits and groin. The trial will evaluate a treatment called sonelokimab, which is given as a subcutaneous injection, meaning it is injected under the skin. Sonelokimab is a type of medication known as a nanobody, which works by inhibiting proteins called IL-17A and IL-17F that are involved in inflammation. The study will compare the effects of sonelokimab with a placebo, which is a sterile solution that looks like the medication but does not contain any active ingredients.

The purpose of the study is to assess how effective and safe sonelokimab is for adults with moderate to severe hidradenitis suppurativa. Participants in the study will receive either sonelokimab or a placebo over a period of 16 weeks. During this time, researchers will monitor the participants to see if there is a 75% improvement in their condition, which is measured by a specific score called the Hidradenitis Suppurativa Clinical Response (HiSCR) score. The study will also track any side effects or adverse events that occur during the treatment period.

Throughout the study, participants will undergo regular check-ups, including physical examinations and laboratory tests, to ensure their safety and to gather data on the treatment’s effects. The trial aims to provide valuable information on whether sonelokimab can be a beneficial treatment option for those suffering from hidradenitis suppurativa, potentially improving their quality of life by reducing the severity of their symptoms.